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a  b  s  t  r  a  c  t
Venous  thromboembolism  (VTE)  is  relatively  common  among  patients  with  haematological  malignan-
cies.  Management  is  challenging  because  many  of  these  patients  are  also  thrombocytopenic  and  at
increased  risk  of bleeding.  Current  recommendations  regarding  the  treatment  of VTE  in  thrombocy-ccepted 16 June 2016 topenic  patients  with  haematological  malignancies  are  limited  as  there  only  few  studies  evaluating  theeywords:
nticoagulation
enous thromboembolism
aematological malignancies
hrombocytopenia
safety  and  efﬁcacy  of anticoagulation  in  this  population  of patient.  A literature  review  on  the safety  of
antithrombotic  therapy  for treatment  or prophylaxis  of  VTE  in patients  with  haematological  malignancies
was  undertaken.  This  includes  a report  on  5 patients  with  haematological  malignancies  at  our institute
who  received  enoxaparin  for treatment  of VTE  while  thrombocytopenic.  Unlike  previous  case  series  which
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c-nd/4.0/).
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Cont  showed  that  the use  of  LMWH  (low  molecular  weight  heparin)  is  safe  in  this  group  of patients,  major
bleeding  occurred  in 2  patients,  and  was  fatal  in  one  case.  More  studies  are  required  to  evaluate  the  risk
factors  and  safety  of  anticoagulation  in these  patients.
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. Introduction
Patients with haematological malignancies are at increased
isk of venous thromboembolism (VTE). The reported incidence
f VTE in the literature varies (2–12% in patients with acute
eukaemias and 1.5–14.6% in patients with Lymphomas) (Falanga
nd Marchetti, 2009), with the highest incidence reported in CNS
ymphoma 59.5%. (Goldschmidt et al., 2003) Risk factors for cancer-
ssociated thrombosis can broadly be classiﬁed into cancer-related,
reatment related and patient related factors (Table 1). In addition,
everal biomarkers for increased risk of thrombosis have been pro-
osed and a validated risk score based on a combination of the
bove risk factors and biomarkers has been developed (Khorana
t al., 2008).
Treatment of VTE is challenging as patients with haematalogical
alignancies are at increased risk of both bleeding and thrombo-
is recurrence (Levitan et al., 1999; Palareti et al., 2000; Prandoni
t al., 2002; Trujillo-Santos et al., 2008). In particular, these patients
re often thrombocytopenic due to disease and/or chemotherapy.
ecommendations for treatment of VTE in patients with cancer
ave been published by the International Society of Thrombosis
nd Haemostasis (Farge et al., 2013), American Society of Clinical
ncology (Lyman et al., 2013), and British Committee for Stan-
ards in Haematology (Watson et al., 2015). However these clinical
ractice guidelines are limited due to lack of well-designed ran-
omised controlled studies in the literature looking speciﬁcally at
TE in thrombocytopenic patients with haematological malignan-
ies. According to these guidelines, low molecular heparin for initial
reatment and maintenance for a period of 3–6 months is recom-
ended for patients with cancer with an established VTE. In cancer
atients with thrombocytopenia, it is interesting to note that both
SCO and ISTH apply a threshold of 50 × 109/L below which ther-
peutic anticoagulation is relatively contraindicated. Additionally,
hen the platelet count is <50 × 109/L, BCSH also recommends the
able 1
xamples of risk factors for cancer associated thrombosis.
Cancer Related
Site- Pancreas, stomach, brain, kidney, lung, ovary, haematological malignancies
Advanced Stage
Initial period after diagnosis (highest ﬁrst 3–6 months)
Treatment related
Chemotherapy
Erythropoiesis stimulating agents
Hormonal therapy
Immunomodulatory drugs- Thalidomide, lenalidomide
Central venous Catheters
Patient Related
Advanced age
Female sex
Race (Higher in African Americans, lower in Asians)
BMI  (Obesity)
Comorbidities (renal disease, infection, pulmonary disease)
Biomarkers
Elevated D Dimer
Platelet count (≥350 × 109/L)
Leucocyte count (>11 × 109/L)
Hb (<100 g/L)
Elevated tissue factorblished  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
use of platelet transfusions to elevate the count to >50 × 109/L to
allow full dose anticoagulation especially in the immediate period
following thrombosis development (Watson et al., 2015). This
threshold is based on exclusion criteria used in clinical trials rather
than evidence based. Furthermore, whether these recommenda-
tions can be applied to patients with haematological malignancies
and VTE remains unclear and although this topic has been the focus
of previous review articles (Falanga and Marchetti, 2009), there has
been no signiﬁcant progress in this area to date.
We  report 5 cases of patients with haematological malignancies
treated with low molecular weight heparin while thrombo-
cytopenic together with a literature review of the safety of
anticoagulation for treatment and prophylaxis of VTE in this patient
population.
2. Methods
2.1. Case reports
We retrospectively reviewed cases of patients with known or
newly diagnosed haematological malignancies treated for con-
comitant VTE either as inpatients or outpatients at the Calvary
Mater Hospital between 2013 and 2015 inclusively. Cases were
selected if they met  the following inclusion criteria (1) Thrombocy-
topenia (platelet count <100 × 109/L) on at least 2 consecutive days
during treatment for VTE (2) Non Catheter related VTE (3) Had fol-
low up throughout period of thrombocytopenia and/or treatment
for haematological malignancy. We  excluded cases of catheter
related thrombosis because this is relatively common in patients
with malignancies and has been extensively reviewed in previ-
ously published guidelines (Farge et al., 2013). Major bleeding was
deﬁned as fatal bleeding, symptomatic bleeding in a crucial area
or organ, or bleeding that caused a reduction in haemoglobin con-
centration of >2 g/dL or that necessitated transfusion of >2 units
of whole blood or red blood cells (Schulman and Kearon, 2005).
Minor bleeding comprised all bleeding events that did not meet
the criteria for major bleeding.
2.2. Literature review
A search of MEDLINE, EMBASE, CINAHL databases, Cochrane
Central Register of Controlled Trial, and Cochrane Database of Sys-
temic Reviews for articles published in English between January
1996 and January 2015. References cited in the articles obtained
from the above search and similar articles in MEDLINE were
included. The search terms included venous thromboembolism
(VTE), treatment, thromboprophylaxis, heparin, unfractionated
heparin, low molecular heparin, warfarin, haematological malig-
nancies and thrombocytopenia. As there were only very few
studies evaluating the safety of anticoagulation in thrombocy-
topenic patients with haematological malignancies treated for
venous thromboembolism, we expanded our search to include any
article that evaluated the safety of anticoagulation as thrombo-
prophylaxis or treatment of VTE in patients with haematological
malignancies.
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. Case reports
.1. Case 1
A 19 year old Caucasian male presented with general lethargy
nd nausea. He was found to be anaemic and thrombocytopenic
Hb 84 g/L platelets 52 × 109/L). Circulating blasts were observed
n the blood ﬁlm and a bone marrow biopsy was performed which
onﬁrmed the diagnosis of B Acute Lymphoblastic Leukaemia (B
LL). He had been diagnosed with an unprovoked right lower limb
eep venous thrombosis (DVT) 3 months prior and was on war-
arin. Warfarin was ceased and he was switched to enoxaparin with
 50% dose reduction in view of his thrombocytopenia. He was
ommenced on induction chemotherapy using the Berlin Frank-
urt Munster (BFM) 2000 protocol. During induction, his mean
nd median platelet count until platelet recovery was  65 × 109/L
nd 51 × 109/L with a nadir of 23 × 109/L. Platelet transfusions
ere given to maintain a platelet count above 20 × 109/L. Fur-
her dose adjustments were made to enoxaparin according to his
latelet count. Enoxaparin was withheld for 12 h prior to lumbar
unctures for administration of intrathecal chemotherapy. Cyro-
recipitate infusions were given for hypoﬁbrinogenemia (<2.0 g/L)
econdary to aspariginase therapy. No major or minor bleeding was
oted throughout induction and consolidation chemotherapy. He
as switched to a prophylactic dose of enoxaparin (40 mg  daily) 6
onths post diagnosis of his DVT and currently remains on main-
enance chemotherapy.
.2. Case 2
A 61 year old Caucasian female was referred with a 1 week his-
ory of increasing shortness of breath on exertion, spontaneous
ruising, epistaxis, gum bleeding and haemoptysis. On presenta-
ion, she was thrombocytopenic with a platelet count of 18 × 109/L.
n urgent bone marrow biopsy with FISH panel was  performed and
 diagnosis of acute myeloid leukaemia (not otherwise speciﬁed)
as made. She was on rivaroxaban following an unprovoked exten-
ive left lower limb deep venous thrombosis involving the left iliac
nd femoral veins and bilateral pulmonary emboli (PE) 2 months
go. Rivaroxaban was ceased and she was switched to full dose ther-
peutic enoxaparin. She was commenced on standard induction
hemotherapy with cytarabine/idarubicin (7-3 regimen). Mean and
edian platelet count from induction until platelet recovery were
1 × 109/L and 37.5 × 109/L respectively with a nadir of 24 × 109/L.
latelet transfusions were given to maintain a platelet count above
0 × 109/L. Minor bleeding occurred (oozing around intravenous
annula insertion sites) during induction but no major bleeding
omplications were noted. She did not have any major bleeding at
he time of completion of ﬁrst consolidation chemotherapy.
.3. Case 3
A 67 year old Caucasian male presented to hospital with a fall
omplicated by a right subdural haematoma. Platelet count at the
ime of presentation was 13 × 109/L. Coagulation proﬁle including
PTT (Activated Partial Thromboplastin Time) and PT (Prothrom-
in Time) were in the normal range. Fibrinogen was  not done at
ime of bleed but was normal when performed 7 months prior.
e had a diagnosis of transformed myeloﬁbrosis on a background
f JAK2 positive Essential Thrombocytosis. He was  receiving dose
djusted enoxaparin (40 mg  twice daily) for a right upper lobe
ulmonary embolus which was diagnosed 1 month prior to this
resentation. Platelet transfusions were given to maintain a platelet
ount >25 × 109/L. Mean and median platelet count from diagno-
is of pulmonary embolus to subdural bleed were 24 × 109/L and
1.5 × 109/L respectively with a nadir of 13 × 109/L. Enoxaparin wasology/Hematology 105 (2016) 92–99
ceased on upon detection of the subdural haematoma. The patient
developed seizures with decreased level of consciousness and was
admitted to the intensive care unit. Unfortunately the patient’s
condition deteriorated and was  palliated.
3.4. Case 4
A 58 year old Caucasian male receiving chemotherapy on the
Cancer and Leukaemia Group B (CALGB) protocol for Acute Lym-
phoblastic Leukaemia was  diagnosed with pulmonary embolus (PE)
during the late intensiﬁcation phase and was started on a daily dose
of therapeutic enoxaparin (50% reduction). This occurred on a back-
ground of previous pulmonary embolus 3 years ago. He developed
rectal bleeding and was admitted 1 month later with pancytope-
nia (Haemoglobin 78 g/L white cell count 0.2 × 109/L and platelet
count 15 × 109/L) in the setting of ongoing chemotherapy. Mean
and median platelet count from time of admission until platelet
recovery were 32 × 109/L and 30 × 109/L respectively with a nadir
of 15 × 109/L Platelet transfusions were given to maintain a platelet
count of >20 × 109/L. Enoxaparin was withheld on admission when
the platelet count was  <20 × 109/L but continued for the rest of
his admission. No surgical intervention was required for his rec-
tal bleeding. He was discharged after the bleeding had settled
and platelet count at time of discharge was 30 × 109/L. He was
switched to rivaroxaban 20 mg  daily during maintenance phase of
chemotherapy. No other minor or major bleeding was noted on
follow up until completion of chemotherapy.
3.5. Case 5
A 69 year old Caucasian female with history of Mantle
cell Lymphoma previously treated with 6 cycles of Rituximab,
Cyclophosphamide, Vincristine and Prednisolone (RCHOP) was
diagnosed with relapse 15 months after completion of RCHOP and
while on maintenance Rituximab. This was complicated by proxi-
mal  vein deep venous thrombosis for which she was on warfarin.
Warfarin was  ceased and switched to enoxaparin at a dose of
1.5 mg/kg. She was  commenced on second line chemotherapy Rit-
uximab, Etoposide, Methylprednisolone and Carabine (RESHAC).
She received 3 cycles of R ESHAC in total as an outpatient.
Twice weekly full blood counts were performed. No thrombo-
cytopenia was  noted during her ﬁrst cycle. In her second cycle,
she was ﬁrst noted to be thrombocytopenic from day 10 post
chemotherapy with a platelet count of 130 × 109/L. Mean and
median platelet count until platelet recovery were 76 × 109/L and
58 × 109/L respectively with a nadir of 23 × 109/L and duration of
thrombocytopenia for about 10 days. Enoxaparin was continued at
full dose throughout the second cycle and no platelet transfusion
was given. During cycle 3, her platelet count was 88 × 109/L on day
10. Mean and median platelet count until platelet recovery were
41 × 109/L and 34 × 109/L respectively with a nadir of 9 × 109/L and
thrombocytopenia lasted for at least 10 days. Platelet transfusions
were given for platelets <20 × 109/L and enoxaparin was withheld
if platelet count was <50 × 109/L. No major or minor bleeding com-
plications were noted throughout all 2 cycles of chemotherapy.
4. Results
5 patients with different haematological malignancies are pre-
sented in this review. The patient characteristics are shown in
Table 2. VTE preceded the diagnosis of haematological malignancy
in 2 patients (1 and 2). All received enoxaparin as treatment
for VTE (2 lower limb DVTs, 3 PEs). Platelets transfusions were
given for platelet counts <20 × 109/L and enoxaparin dose reduced
for platelet counts <50 × 109/L in accordance to recommended
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Table  2
Patient characteristics.
Patient Age/yr
Sex
Weight/kg
BMI
Haematological
diagnosis
VTE site Chemotherapy
Phase of
treatment at time
of treatment for
VTE
Renal
impairment
eGFR
Other
comorbidities
1 19M 98
27
ALL DVT proximal Lower limb BFM 2000 induction and
consolidation
No eGFR >90 None
2  61F 91
32
AML  DVT/PE 7 + 3 induction
5 + 2 + 5 consolidation
No eGFR 60–90 Multinodular goitre
hypothyroidism, Sjogren’s
syndrome
3  67M 69
23
MF  PE Not on chemotherapy No eGFR 60k90 COPD, asbestos exposure, IHD,
Gout, CVA
4  56M 95
27
ALL PE CALBG
Late intensiﬁcation
No eGFR >90 History of PE
5  69M 61
24
NHL DVT proximal Lower limb ESHAC
Cycles 1–3
Yes eGFR 30–75 COPD
Table 3
Platelet count and bleeding in patients treated with enoxaparin for VTE.
Patient Chemotherapy Treatment
Phase/setting
Mean platelet
count
/X109/L
Median platelet
count
/X109/L
Nadir platelet
count
/X109/L
Duration of
thrombocytopenia
/days
Bleeding severity
and
Grading
1 Induction (inpatient) 65 51 23 32 No bleeding
complicationsConsolidation (outpatient) 165 114 10 16
2 Induction (inpatient) 41 37.5 27 23 Minor bleeding
aConsolidation 1 (outpatient) 113 128 8 15 WHO  1
3  Not on chemotherapy
(Outpatient)
24 21.5 13 22 Major bleeding
(fatal)
WHO  2
4  Late intensiﬁcation
(Outpatient)
32 30 15 10 Major bleeding
5 Cycles  2 (outpatient) 76 58 23 10 No bleeding
complicationsCycle 3 (Outpatient) 41 33.5 9 10
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<a Discharged prior to onset of thrombocytopenia.
uidelines. Four patients (1, 2, 4, and 5) were receiving chemother-
py while treated for their VTE. Two patients (1 and 2) received
reatment for VTE as inpatients while undergoing induction
hemotherapy for acute leukaemia. Patient 4 was admitted post
hemotherapy for acute leukaemia in the setting of signiﬁcant
ytopenias and received treatment for VTE while as an inpatient.
atient 3 and 5 were treated for their VTE as outpatients. A sum-
ary of the platelet counts (mean, median and nadir) and bleeding
utcomes is shown in Table 3. There were two major bleeds (3 and
), and one minor bleed (2). One major bleed was fatal (patient
). None of the patients had recurrent or new VTE. In one patient
4), enoxaparin was switched to rivaroxaban during maintenance
hemotherapy during which his platelet count was  maintained
bove 100 × 109/L.
. Literature review
A summary of studies evaluating the safety of anticoagulation
or VTE in patients with haematological malignancies is shown in
able 4. Majority of the studies evaluated the safety of throm-
oprophylaxis rather than treatment of VTE and most of these
ere based on catheter related thrombosis. When deﬁned, catheter
elated thrombosis in these studies was deﬁned as thrombosis of
he vein(s) in which the catheter was placed and/or a contiguous
ein. Most studies included patients with thrombocytopenia, 2 of
hich reported on a cohort of patients who received anticoagu-
ation in the setting of severe thrombocytopenia (platelet count
20 × 109/L). Low molecular weight heparin was the most com-mon  antithrombotic agent used. We  found only 2 retrospective
studies and no prospective or randomised controlled trials (RCTs)
evaluating the safety of anticoagulation for the treatment of VTE in
thrombocytopenic patients with haematological malignancies.
5.1. Prophylaxis
5.1.1. Thromboprophylaxis in patients with haematological
malignancies and central venous catheters
Couban et al. conducted a randomised controlled trial which
compared warfarin at a dose of 1 mg  and placebo as thrombo-
prophylaxis in 255 patients with central venous catheters, 80% of
whom had haematological malignancies (Couban, 2005). In this
study, the incidence of thrombocytopenia was  not recorded and
the study drug was  withheld in patients with a platelet count
below 20 × 109/L. No signiﬁcant difference in bleeding complica-
tions occurred in the arm receiving warfarin compared to placebo.
In the CATHEM study, Cortelezzi et al. reported on 416 patients
with haematological malignancies undergoing CVC insertion who
were prospectively followed up to assess the incidence and risk fac-
tors for thrombotic complications (Cortelezzi et al., 2005). 14% of
patients received thromboprophylaxis with low molecular heparin
(majority), unfractionated heparin, warfarin or aspirin. The inci-
dence of VTE (DVT and/or PE) was  3.2% and 80% of the patients were
severely thrombocytopenic. 1.5% of the 416 patients were catheter
related thrombosis. The authors concluded that antithrombotic
prophylaxis was  not associated with an increased risk of bleeding
although the study was  not designed for this indication.
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Table 4
Studies evaluating the use of antithrombotics in the treatment/prophylaxis of VTE in patients with haematological malignancies and bleeding complications.
Study Population Study Design Indication/antithrombotic agent Bleeding severity/incidence Study Conclusion Comment
Couban et al JCO
2005 (Couban,
2005)
Cancer patients
(80%
haematological
malignancy) with
CVC
n  = 215
Prospective Thromboprophylaxis; Warfarin
1 mg
Major bleeding* 0%
Minor bleeding 4%
No increased risk of major
bleeding
Anti thrombotic withheld below
platelet count 20 × 109.
Cortelazzi BJH
2005 (Cortelezzi
et al., 2005)
Patients with
haematological
malignancy and
CVC
n  = 416
RCT Thromboprophylaxis; LMWH
(majority), UFH, aspirin, warfarin
Severe bleeding 0% No increased risk of major
bleeding
Only 14.2% received
Antithrombotic prophylaxis
Thrombocytopenia (<50 × 109/L)
was  present in
81% of patients.
Study not designed to look at
safety and efﬁcacy of
antithrombotic prophylaxis.
Or  et al
Transplantation
1996 (Or et al.,
1996)
HSCT recipients
n  = 61
RCT Prevention of Veno-occlusive
Disease;
LMWH
Bleeding events
(events/pt)
2.3 ± 2.5 vs 5.3 ± 6
P = 0.025
Duration of bleeding (days/pt)
2.3 ± 2.6 vs 5.8 ± 6
P = 0.06
LMWH associated with
decreased risk of bleeding
5 patients in LMWH  group and 8
patients in placebo group
withdrawn due to major
bleeding
Simon M et al, Bone
marrow transplant
2001 (Simon and
Hahn, 2001)
HSCT recipients
n  = 462
Retrospective Prevention of Veno-occlusive
Disease;
UFH, UFH + PGE1, LMWH
Death due to haemorrhagic
events 3% (total)
No signiﬁcant difference in death
due to haemorrhagic events in
groups receiving prophylaxis vs
no prophylaxis
Forrest et al, Bone
marrow transplant
2003 (Forrest et al.,
2003)
HSCT recipients
n  = 40
Prospective Prevention of Veno-occlusive
Disease;
LMWH
Clinically signiﬁcant bleedingˆ
(≥Grade 2)7.5%
Minor bleeding (Grade 1) 60%
No signiﬁcant increase in
clinically signiﬁcant bleeding
Platelet transfusion if <10 × 109/L
or <30 × 109/L with clinically
signiﬁcant bleeding
Gonsalves  et al, JTH
2008 (Gonsalves
et al., 2008)
HSCT recipients
n  = 589
Retrospective Treatment of VTE
(n = 22);
LMWH+/− Warfarin
No signiﬁcant bleeding
complications recorded
No signiﬁcant bleeding
complications
Gerber  et al, Blood
2008 (Gerber et al.,
2008)
HSCT recipients
n  = 1514
Retrospective Treatment of VTE
(n = 62)
Type of antithrombotic not
stated
Clinically signiﬁcant bleeding#
37%
(n = 23) Fatal bleeding 5% (n = 3)
Bleeding
associated with anticoagulation
(OR  3.1;
95% CI, 1.8-5.5),
Median platelet count at the time
of  VTE  events overall 75 × 109/L
(IQR, 42–150 109/L).
Herishanu et al,
Leukaemia
Lymphoma 2004
(Herishanu et al.,
2004)
Patients with
haematological
malignancy and
severe
thrombocytopenia
n  = 10
Retrospective Treatment of CVC related VTE
(n = 10);
LMWH
Major Bleeding 0% No increased risk of major
bleeding
Imberti et al,
Tumori 2004
(Imberti et al.,
2004)
Acute Leukaemia
n  = 4
Retrospective Treatment of VTE (n = 4) No haemorrhagic complications No haemorrhagic complications Dose reduced by 50% if
platelets <20 × 109/L
* Major bleeding: CNS bleeding, bleeding with hypotension (systolic blood pressure <80 mmHg  or a> 30-mmHg decrease in systolic blood pressure), bleeding associated with the transfusion of more than 2 units of red cells in
any  24-h period, or a decrease in haemoglobin by 20 g/L or more in any 24-h period.
ˆ grade 0 = no bleeding; grade 1 = minor mucosal bleeding or petechiae not requiring packed red blood cell (PRBC) transfusion; grade 2 = any bleeding episode requiring transfusion of 1–2U of PRBCs/episode in a 24-h period; grade
3  = any bleeding episode requiring transfusion of >2U of PRBCs/episode, but < 4U in a 24-h period or retroperitoneal bleeding; grade 4 = any bleeding causing hemodynamic instability or requiring transfusion of >4U of PRBCs in a
24-h  period or any CNS bleeding.
# Clinically signiﬁcant bleeding: a bleeding event between HSCT admission and HSCT day 180 that led to a speciﬁc clinical intervention. Interventions included but were not limited to hospitalization, transfusion, endoscopy,
bronchoscopy, intubation, or continuous bladder irrigation. Bleeding episodes not requiring intervention (e.g., most mucosal and soft tissue bleeding, microscopic hematuria) were not recorded.
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.1.2. Use of low molecular weight heparin in the prevention of
eno-occlusive disease in patients undergoing haematopoietic
tem cell transplantation
Several studies have evaluated the safety of low molecular
eight heparin in patients undergoing haematopoietic stem cell
ransplant for the prevention of venom-occlusive disease (Or et al.,
996; Simon and Hahn, 2001; Forrest et al., 2003). The results of
hese studies indicated that the use of low molecular heparin is safe
ith no increased risk of bleeding. In one study, the mean number
nd duration of severe haemorrhagic occurrences per patient were
igniﬁcantly lower in the LMWH  group (P = 0.025 and P = 0.006,
espectively compared to placebo).
.2. Treatment
.2.1. Treatment of venous thromboembolism in the patients
ndergoing haematopoietic stem cell transplantation
Gonsalves et al. (2008) performed a retrospective study on
he incidence of symptomatic VTE in ambulatory patients in the
ransplant setting (n = 589, 382 autologous, 207 allogeneic). The
ncidence of VTE was 3.7%. Non catheter related venous thrombo-
is occurred in 7 patients (1.2%). The mean platelet count was 121
range 50–174). Three patients had platelet counts below normal.
ll seven patients were treated with full-dose anticoagulation using
ow molecular weight heparin, but in two cases, low molecular
eight heparin therapy was switched to treatment with warfarin.
o signiﬁcant bleeding complications developed during anticoag-
lant therapy in these seven patients. In contrast, a study of 1514
npatients admitted for haematopoietic stem cell transplant (928
utologous 586 allogeneic) found anticoagulation (type not stated)
o be associated with an increased risk of bleeding (OR,3.1; 95%
I, 1.8–5.5) (Gerber et al., 2008). In this study, the total incidence
f VTE was 4.6%. 1.3% (n = 20) were non catheter related venous
hrombosis. 34% of VTE occurred at a platelet count <50 × 109/L and
latelet transfusions were given to maintain a platelet count above
his threshold in patients receiving anticoagulation. The reason for
he different results obtained in the 2 studies is unclear. However,
his may  be related to the timing of VTE during the transplant.
.2.2. Treatment of venous thromboembolism in severely
hrombocytopenic patients with haematological malignancies
Herishanu et al. (2004) reported a retrospective cohort of
0 patients undergoing intensive chemotherapy for haematolog-
cal malignancies who received low molecular weight heparin
s thromboprophylaxis or treatment of CVC related thrombosis
hile severely thrombocytopenic. No major bleeding occurred in
hese patients. In another study (Imberti et al., 2004), 4 patients
iagnosed with acute leukaemia and VTE were treated with low
olecular weight heparin (enoxaparin) dose adjusted according
o their platelet count (Mean platelet count was  55,750 × 109/L;
ange, 12,000–121,000 × 109/L). No VTE recurrences or haemor-
hagic complications were reported. Although these were small
tudies, the results suggested that low molecular weight heparin
ould be used safely in this group.
. Discussion
There are no randomised controlled trials evaluating the safety
f anticoagulation for VTE in thrombocytopenic patients with
aematological malignancies. In our literature review, 2 small ret-
ospective studies (Herishanu et al., 2004; Imberti et al., 2004)
oncluded that low molecular weight heparin could be used safely
n the treatment of VTE in the setting of thrombocytopenia whereas
nother large retrospective study demonstrated that anticoagula-
ion for the treatment and prophylaxis of VTE in haematopoietic
tem cell recipients was associated with a higher risk of bleedingology/Hematology 105 (2016) 92–99 97
although the type of anticoagulation was not stated (Gerber et al.,
2008). In our case series of 5 patients, major bleeding (intracra-
nial haemorrhage, gastrointestinal bleeding) occurred in 2 patients
with the former being fatal while minor bleeding occurred in 1
patient.
The risk of bleeding in patients with VTE on anticoagulation has
been evaluated in a meta-analysis by Linkins et al. (2003). Major
bleeding was  estimated at 7.2 events per 100 person-years, and
the risk of fatal bleeding 1.31 per 100 person-years, with a case
fatality rate of 13.4% from major bleeding. Intracranial bleeding
occurred at a rate of 1.15 per 100 patient-years and accounted
for 8.7% of all major bleeding episodes. Eleven of 24 intracranial
bleeding episodes were fatal (Linkins et al., 2003). In another meta-
analysis which compared the safety and efﬁcacy of unfractionated
heparin to enoxaparin in patients with VTE, the adjusted incidence
of major bleeding at 3 months in patients on enoxaparin was 2.9%
(Mismetti et al., 2005). In a pooled analysis of the bleeding risk of
LMWH  and VKA in patients with cancer, major bleeding occurred
in about 6% of patients (Kamphuisen and Beyer-Westendorf, 2014).
These studies did not report on the incidence of major bleeding in
patients with haematological malignancies.
The highest risk of bleeding occurs in the initial period after
starting anticoagulant therapy. Risk factors include age older
age (>65 years and particularly >75 years),recent major bleeding
(<15 days prior to VTE), comorbidities (previous gastrointestinal
bleeding, stroke, chronic renal disease, metastatic malignancy,
alcohol-related disease, or diabetes), thrombocytopenia, anaemia,
concomitant antiplatelet therapy, recent surgery, frequent falls,
alcohol abuse, and reduced functional capacity (Prandoni et al.,
2002; Shoeb and Fang, 2013; White et al., 1999; Palareti et al., 1996;
Kuijer et al., 1999). A bleeding risk assessment scores based on ﬁnd-
ings from the RIETE registry (Ruíz-Giménez et al., 2008) and other
similar scores have been developed (Shoeb and Fang, 2013; Kearon
et al., 2012; Beyth et al., 1998). However, these studies have primar-
ily been based on the use of oral Vitamin K antagonist warfarin and
no bleeding scores to assess the risk of bleeding in the subgroup of
patients with haematological malignancies have been developed.
Risk factors in our patient with JAK 2 positive myeloﬁbrosis and
fatal bleeding included age, comorbidities in particular history of
previous stroke, thrombocytopenia and underlying haematologi-
cal malignancy. Acquired platelet function abnormalities are well
recognised in myeloprolioferative disorders. Unfortunately base-
line platelet function evaluation was not performed in this patient.
While this could be a contributing factor to bleeding risk, this usu-
ally occurs in the setting of a very high platelet count, typically
>1000 × 109/L (Alvarez-larrán et al., 2013) which was  not the case
in our patient. Coexisting coagulopathy and ﬁbrinogen abnormali-
ties can also occur in myeloﬁbrosis secondary to liver dysfunction.
However, Prothrombin time (16 s; normal range 12–16 s) and Acti-
vated Partial Thromboplastin Time (34 s; normal range 24–36 s)
were in the normal range at time of bleed. Fibrinogen was  not
done at time of bleed but was  normal when performed 7 months
prior. It is interesting to note that the 2 patients with major bleed-
ing also had the lowest platelet counts. Bleeding occurred at a
median platelet count of 22 × 109/L in patient 3 with fatal bleed-
ing and was  30 × 109/L in patient 2 with gastrointestinal bleeding.
Platelet count per se was  not shown to correlate with bleeding
in a multivariate analysis performed by Friedmann et al. (2002)
on thrombocytopenic oncology patients. However, this may  not
apply to patients on anticoagulants. Other factors such as duration
of thrombocytopenia, the type of haematological malignancy, and
concomitant chemotherapy may  also be important. More studies
evaluating the risk factors of bleeding in thrombocytopenic patients
with haematological malignancies on anticoagulation for VTE are
therefore required which would be important in deciding which
patients to anticoagulate based on their risk beneﬁt proﬁle.
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Another controversial issue is the effectiveness of the use of pro-
hylactic transfusions to prevent bleeding and what threshold to
ransfuse. Current recommendations suggest transfusion to main-
ain a platelet count greater than 20 × 109/L in patients not actively
leeding and above 50 × 109/L in those with active bleeding. These
re based on supportive care in patients with acute promyelo-
ytic leukaemia and are expert opinion rather than evidence based.
n the TOPPS trial, a randomised trial of 600 patients receiving
hemotherapy or undergoing stem cell transplantation, prophylac-
ic platelet transfusions resulted in less WHO  grade 2–4 bleeding
xcept in the population undergoing autologous stem cell trans-
lantation (Stanworth et al., 2013). However it remains to be seen
hether this can be also applied to patients with haematological
alignancies on anticoagulation for VTE. Although our patient with
atal bleeding received prophylactic, platelet transfusions to main-
ain his platelet count above 20 × 109/L, the logistics of this was
ifﬁcult as he was managed in an ambulatory care setting. Thus,
ore studies are required to investigate the role and indication of
rophylactic platelet transfusions, as well as the safety of such a
trategy in the ambulatory setting compared to inpatient setting.
Finally further studies to evaluate the dosing, duration and type
f anticoagulation in such patients are needed. Current recommen-
ations suggest full anticoagulation with low molecular weight
eparin for patients with platelet counts >50 × 109/L and dose
educing if <50 × 109/L. The availability of direct oral anticoagulants
rovides an attractive alternative choice of anticoagulation with the
dvantage of convenience, tolerability and less drug interactions.
owever the safety and efﬁcacy of these agents in this population
f patients is not known and current guidelines do not support their
se in this setting.
. Conclusion
In summary, 5 cases of patients with haematological malignan-
ies treated with low molecular weight heparin for non-catheter
elated venous thromboembolism while severely thrombocy-
openic are discussed. A summary of literature is presented with
iscussion on various challenges around treating VTE in severely
hrombocytopenic patients. Unlike previous case series, major
leeding occurred in 2 patients. Limitations of our study include
ts retrospective design and the small number of patients analysed.
ore studies are required to evaluate risk factors for bleeding, the
afety and efﬁcacy of anticoagulation for treatment and prophylaxis
f venous thromboembolism, efﬁcacy and indications for prophy-
actic platelet transfusions in thrombocytopenic patients, as well
s the dosing, duration and type of anticoagulation used.
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